Literature DB >> 15923123

Pre-interleukin-1alpha expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1).

Gaby Palmer1, Stéphanie Trolliet, Dominique Talabot-Ayer, Françoise Mézin, David Magne, Cem Gabay.   

Abstract

Interleukin-1 receptor antagonist (IL-1Ra) inhibits the classical biological effects of interleukin (IL)-1 by preventing its binding to IL-1 receptors. There are, however, four different isoforms of IL-1Ra, of which three are intracellular (icIL-1Ra1, 2, 3). Due to their localization, icIL-1Ras cannot interact with cell surface IL-1 receptors and have been suggested to carry out specific functions inside cells. The recent description of nuclear effects of the IL-1alpha precursor (preIL-1alpha) led to the hypothesis that icIL-1Ra variants might antagonize the intracellular actions of preIL-1alpha. The aim of this study was to investigate effects of preIL-1alpha and icIL-1Ra1 in stably transfected SaOS-2 cells. Expression of preIL-1alpha significantly decreased cell growth and this effect was not reversed by addition of exogenous IL-1Ra, suggesting an intracellular mode of action. Transfection of SaOS-2 cells with icIL-1Ra1 did not affect their growth. Furthermore, co-expression of icIL-1Ra1 did not reverse the growth inhibitory effect of preIL-1alpha. In contrast, the production of IL-6 induced by preIL-1alpha was decreased in icIL-1Ra1 co-transfected cells. In conclusion, expression of preIL-1alpha decreased the growth of SaOS-2 cells, likely by an intracellular mechanism. Co-expression of icIL-1Ra1 did not antagonize this effect, indicating that intracellular effects of preIL-1alpha are not necessarily susceptible to inhibition by icIL-1Ra1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15923123     DOI: 10.1016/j.cyto.2005.03.007

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  9 in total

1.  Interleukin-33 is biologically active independently of caspase-1 cleavage.

Authors:  Dominique Talabot-Ayer; Céline Lamacchia; Cem Gabay; Gaby Palmer
Journal:  J Biol Chem       Date:  2009-05-22       Impact factor: 5.157

2.  IL-33 regulates TNF-α dependent effects in synovial fibroblasts.

Authors:  Elke Kunisch; Saritha Chakilam; Muktheshwar Gandesiri; Raimund W Kinne
Journal:  Int J Mol Med       Date:  2012-01-10       Impact factor: 4.101

3.  Propiece IL-1α facilitates the growth of acute T-lymphocytic leukemia cells through the activation of NF-κB and SP1.

Authors:  Yinsheng Zhang; Xiao Yu; Dandan Lin; Lei Lei; Bo Hu; Fengzhang Cao; Yu Mei; Depei Wu; Haiyan Liu
Journal:  Oncotarget       Date:  2017-02-28

Review 4.  Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy.

Authors:  N M Luheshi; N J Rothwell; D Brough
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

5.  The dynamics and mechanisms of interleukin-1alpha and beta nuclear import.

Authors:  Nadia M Luheshi; Nancy J Rothwell; David Brough
Journal:  Traffic       Date:  2008-10-07       Impact factor: 6.215

Review 6.  HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins.

Authors:  Damien Bertheloot; Eicke Latz
Journal:  Cell Mol Immunol       Date:  2016-08-29       Impact factor: 11.530

7.  CRISPR/Cas9 mediated mutation of mouse IL-1α nuclear localisation sequence abolishes expression.

Authors:  Michael J D Daniels; Antony D Adamson; Neil Humphreys; David Brough
Journal:  Sci Rep       Date:  2017-12-06       Impact factor: 4.379

8.  Interleukin-1α associates with the tumor suppressor p53 following DNA damage.

Authors:  J Novak; B Zamostna; V Vopalensky; M Buryskova; L Burysek; D Doleckova; M Pospisek
Journal:  Sci Rep       Date:  2020-04-24       Impact factor: 4.379

Review 9.  IL-1/IL-1R Signaling in Head and Neck Cancer.

Authors:  Sven E Niklander; Craig Murdoch; Keith D Hunter
Journal:  Front Oral Health       Date:  2021-08-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.